MR引导腹部SABR中剂量累积评估治疗相关副作用的可行性
结果显示多数胃肠道危及器官(OAR)的AD指标低于计划值,小肠剂量指标与急性和亚急性腹泻存在弱关联(rs 0.4-0.5,p < 0.040),所有副作用≤2级。结论认为基于形变配准的累积剂量与副作用关系探索可行,但需更大样本验证。
要点
- 多数胃肠道OAR累积剂量低于计划值,十二指肠和结肠D0.5cc、D10cc显著降低。
- 小肠剂量与急/亚急性腹泻弱相关(rs 0.4-0.5),所有副作用≤G2。
核心结论
- 基于形变配准的累积OAR剂量与副作用关系探索可行,但需更大样本验证后才能用于个体化治疗。
研究设计与样本
- 每日自适应计划经形变映射并求和估算累积剂量,比较累积与计划剂量差异。
- 分析基线、3个月和6个月临床医生报告的症状变化,采用Spearman秩检验评估累积剂量与症状的关联。
主要发现
- 多数胃肠道OAR的累积剂量指标低于计划值,十二指肠和结肠D0.5cc和D10cc显著降低(p < 0.001)。
- 小肠剂量指标与急性和亚急性腹泻存在弱关联(rs 0.4-0.5,p < 0.040)。
- 所有副作用均≤2级;局部晚期胰腺癌患者SABR后中位总生存期为16.0个月,其他亚组未达到。
临床怎么用
- MR引导腹部SABR中可尝试用形变配准累积剂量评估OAR受量与副作用的关系。
- 目前证据仅为初步弱关联,尚不能据此调整个体化治疗决策。
局限性
- 单中心小样本回顾性研究,结果需更大规模研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Daily adaptive magnetic resonance (MR)-guided treatment changes delivered dose distributions, making cumulative dose uncertain. This work assessed the feasibility of exploring potential relationships between side effects and accumulated dose (AD) in MR-guided stereotactic ablative radiotherapy (SABR) for liver and pancreatic cancers. Using deformable image registration (DIR), AD to abdominal organs at risk (OARs) were estimated and potential relationships with observed side effects explored. METHODS: Forty-one patients treated with 5-fraction MR-guided SABR to primary or metastatic pancreatic and liver tumours were retrospectively included. Daily adapted plans were deformably mapped and summed to estimate AD. Differences between accumulated and planned dose were assessed. Changes in clinician-reported symptoms collected at baseline, 3, and 6 months were analysed. Associations between AD and symptoms were assessed using Spearman's rank test. RESULTS: Most AD metrics were lower than planned for gastrointestinal OARs, reflecting potential differences from delivered ATS plans, with significant reductions in duodenum and large bowel D0.5cc and D10cc (p < 0.001). Weak associations between small bowel dose metrics and acute and subacute diarrhoea were found (rs 0.4-0.5, p < 0.040). All side effects were ≤ grade (G) 2. Median overall survival for locally advanced pancreatic cancer (LAPC) patients was 16.0 months post-SABR and was not reached for other subgroups. CONCLUSION: Exploring potential relationships between DIR-based accumulated OAR dose and side effects was feasible. Preliminary relationships between accumulated OAR dose and side effects were observed; however, further work in larger studies is warranted before these findings can be used to personalise treatment in the future.
引用
- Shabbir R, Zakacz A, Sivakaran R, et al. Feasibility of dose accumulation for assessing treatment-related side effects in MR-guided abdominal SABR: A single-institution study. Clin Transl Radiat Oncol. 2026. PMID: 42740900. doi:10.1016/j.ctro.2026.101277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。